Project Grant R03HL177130
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$144K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to determine the impact of infant antibiotic exposure on the development of the airway and gut microbiome, and its potential link to childhood asthma risk. The $816,358 award will be provided to Vanderbilt University Medical Center (VUMC) over the project period from September 15, 2024 to June 30, 2029. The key...
This $1,559,818 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center aims to establish the critical time windows of infant respiratory syncytial virus (RSV) infection and its causal relationship to the development of childhood asthma. The multi-year study will leverage large population health datasets to analyze the impact of RSV infection timing on asthma risk, as well as the potential...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $565,834 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Regents of the University of Michigan to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research aims to define how RSV infection causes persistent changes in the lung epithelium that predispose individuals to allergic airway disease later in life. Specifically, the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $761,618 to Vanderbilt University Medical Center (VUMC) to conduct research on the clinical and biochemical features of metabolic dysregulation in formerly preterm children. The award term runs from April 15, 2024 to March 31, 2028. As a major academic medical center and nationally prominent recipient of federal research funding, VUMC...
This federal Project Grant award of $154,861 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to address disparities in asthma outcomes among under-resourced, Black, and Hispanic children in Washington, D.C.
The primary objectives are to: 1) develop a machine learning model to predict asthma-related hospitalization risk using social adversity, clinical, and demographic data; 2) characterize caregiver...
This $177,403 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), as part of the Cardiovascular Diseases Research program (CFDA 93.837), aims to utilize multi-omics data to investigate the biological mechanisms underlying asthma heterogeneity and endotypes. The Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will lead the research project over a 5-year period from September 2024 to August 2029. The key products and services to be...
This $777,497 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at The Washington University to investigate how the circadian clock mediates the adult-age, pro-resolution response to viral asthma triggers.
The research aims to clarify how the circadian clock within alveolar macrophages and airway epithelial cells promotes the resolution of viral inflammation and normal...
This federal Project Grant award of $616,814, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to establish the in vivo role of specific microRNAs in regulating airway smooth muscle (ASM) function and airway hyperresponsiveness (AHR), as well as demonstrate their contribution to human asthma and response to asthma therapies. The overarching goal is to provide pre-clinical evidence for developing microRNA-based therapeutics for...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research on the role of the aryl hydrocarbon receptor (AhR) signaling in airway inflammation and asthma. The $613,934 grant awarded to North Dakota State University (NDSU) aims to determine the mechanisms by which AhR activation in airway smooth muscle (ASM) regulates inflammation-induced hyperresponsiveness and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $521,214.63 to Rutgers, The State University of New Jersey, to conduct research on the methylomic and metabolomic determinants of lung function in individuals with asthma. The 3-year award, beginning on July 1, 2024, aims to integrate multiple "omics" data from three large prospective childhood cohorts to identify genetic,...